Globe News, December 25 | Investment research firm Vanda Research shows that the net funds inflow into Novo-Nordisk surged 32 times on Friday, rising from $0.49 million the previous day to $15.6 million, as disappointing data on its weight loss drug offered a rare opportunity for investors to buy at a lower price. The data released by Novo-Nordisk indicated that the experimental drug CagriSema only helped patients lose 22.7% of their weight, below the expected 25%. The stock of Novo-Nordisk plummeted by as much as 21% during Friday's trading to $81.5, the lowest level since August 2023. Marco Iachini, Senior Vice President of Vanda's research department, stated: "Retail investors like to buy on dips, especially in popular stocks... and will continue to do so until this strategy no longer works. Currently, Novo-Nordisk's performance is below the S&P 500 Index for the first time in two years, so it might still be too early to see them (retail investors) abandon this tendency to buy on dips." Friday's retail fund flow may have provided an exit channel for institutional investors.